Mereo BioPharma Group plc is a biopharmaceutical company focused on the development of therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). In addition to the rare disease programs, it has two oncology product candidates in clinical development. Etigilimab is an IgG1 monoclonal antibody which binds to the human T-cell immunoreceptor with Ig and ITIM domains (TIGIT) receptor on immune cells to improve the activation and effectiveness of T-cell and NK cell antitumor activity. Navicixizumab is a bispecific antibody that inhibits delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF). Navicixizumab is developed for the treatment of late line ovarian cancer.
Símbolo de cotizaciónMREO
Nombre de la empresaMereo BioPharma Group PLC
Fecha de salida a bolsaJun 09, 2016
Fundada en2015
Director ejecutivoDr. Denise V. Scots-Knight, Ph.D.
Número de empleados36
Tipo de seguridadDepository Receipt
Fin del año fiscalJun 09
DirecciónOne Cavendish Place
CiudadLONDON
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited Kingdom
Código postalW1G0QF
Teléfono443330237300
Sitio Webhttps://www.mereobiopharma.com/
Símbolo de cotizaciónMREO
Fecha de salida a bolsaJun 09, 2016
Fundada en2015
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.

Sin datos